BioNeutral's Ygiene(TM) Kills Dangerous MRSA in SecondsFont size: A | A | A8:29 AM ET 8/27/09 | BusinessWire BioNeutral Group, Inc. ("BioNeutral") (OTCBB:BONU), a specialty chemical technology based life science company, reports that its Ygiene(TM) Hospital Grade Antimicrobial passed the AOAC Use Dilution test by totally eradicating all five million colony forming units of MRSA in less than one minute (fifty-nine seconds) at room temperature. The required EPA testing procedures occurred at ATS Labs.
MRSA, or Methicillin-resistant Staphylococcus aureus, is a very serious health threatening microorganisms present in many health care facilities and community environments. MRSA is one of the more serious antibiotic resistant heath threatening microorganisms that contributes to Hospital Acquired Infections (HAI's). In the U.S. alone, over two million people annually are afflicted with Hospital Acquired Infections with approximately one hundred thousand people dying. Worldwide Hospital Acquired Infections are on the rise and will lead to hundreds of thousands needless deaths annually. MRSA is also becoming a serious issue associated with Community Acquired Infections such as school and campus settings. With its power to rapidly and totally eliminate MRSA in less than one minute, BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial will be a significant part of the future solution for controlling Hospital Acquired Infections and Community Acquired Infections.
"These independent ATS Labs test results completely validate our internal product development efforts," said BioNeutral Chief Scientist for BioNeutral, Dr. Andrew Kielbania. "The level of efficacy demonstrated in these independent tests is exceptional. Passing this difficult EPA required test for the elimination of MRSA is consistent with the ability of our Ygiene(TM) Hospital Grade Antimicrobial to address a very serious unmet need associated with Hospital Acquired Infections in the health care area. We believe our Ygiene(TM) Hospital Grade Antimicrobial will contribute to the saving of many lives in addition to resources at health care facilities."
"We often use independent labs to support our in-house work, and are very pleased with these test results," said Stephen Browand, CEO at BioNeutral. "We use tests that demand exceptional performance from our antimicrobial products. Current disinfectants on the market are clearly not doing the job when it comes to controlling HAIs; we believe that our antimicrobial products will help remedy that unacceptable situation. Given these impressive results, we have every confidence that our Ygiene Hospital Grade Antimicrobial will have a major impact in reducing Hospital Acquired Infections and saving lives while protecting the environment."
About ATS Labs
ATS Labs is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial services and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the US, Canada and the world. For more information, visit http://www.ats-labs.com.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
SOURCE: BioNeutral Group, Inc.
View dataBioNeutral Group Inc. Stephen J. Browand, 973-286-2899 President and CEO steve*bioneutralgroup.com or The Investor Relations Group Investor Relations: Erika Moran, 212-825-3210 emoran*investorrelationsgroup.com or Media: Laura Colontrelle, 212-825-3210 lcolontrelle*investorrelationsgroup.com
BioNeutral Group Inc. Stephen J. Browand, 973-286-2899 President and CEO steve*bioneutralgroup.com or The Investor Relations Group Investor Relations: Erika Moran, 212-825-3210 emoran*investorrelationsgroup.com or Media: Laura Colontrelle, 212-825-3210 lcolontrelle*investorrelationsgroup.com
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |